Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
Isabella VisuriCarl ErikssonOla OlénYang CaoEmelie MårdbergOlof GripAnders GustavssonHenrik HjortswangPontus KarlingScott MontgomeryPär MyrelidJonas F LudvigssonJonas HalfvarsonPublished in: Alimentary pharmacology & therapeutics (2021)